Cargando…

Short-term survival and safety of apatinib combined with oxaliplatin and S-1 in the conversion therapy of unresectable gastric cancer

BACKGROUND: We conducted a single-arm phase II trial to investigate the short-term efficacy and safety of apatinib combined with oxaliplatin and S-1 in the treatment of unresectable gastric cancer. PATIENTS AND METHODS: Previously untreated patients with unresectable HER-2-negative advanced gastric...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Zaisheng, Zeng, Yi, Wei, Shenghong, Wang, Yi, Lin, Zhitao, Chen, Shu, Wang, Zhiwei, Chen, Shanshan, Chen, Luchuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8204414/ https://www.ncbi.nlm.nih.gov/pubmed/34126957 http://dx.doi.org/10.1186/s12885-021-08459-3

Ejemplares similares

Prognostic value of preoperative body mass index for diabetic patients with non-metastasis gastric cancer: a single center experience
por: Ye, Zaisheng, et al.
Publicado: (2021)

High Expression of FCRLB Predicts Poor Prognosis in Patients With Colorectal Cancer
por: Wang, Xiaopeng, et al.
Publicado: (2022)

Corrigendum: Bioinformatics Analysis Reveals an Association Between Cancer Cell Stemness, Gene Mutations, and the Immune Microenvironment in Stomach Adenocarcinoma
por: Ye, Zaisheng, et al.
Publicado: (2022)

Bioinformatics Analysis Reveals an Association Between Cancer Cell Stemness, Gene Mutations, and the Immune Microenvironment in Stomach Adenocarcinoma
por: Ye, Zaisheng, et al.
Publicado: (2020)

A 13-Gene Metabolic Prognostic Signature Is Associated With Clinical and Immune Features in Stomach Adenocarcinoma
por: Ye, Zaisheng, et al.
Publicado: (2021)

Apatinib treatment for unresectable gastrointestinal stromal tumor with synchronous gastric cancer
por: Xu, Huanji, et al.
Publicado: (2020)

Efficacy and Safety of Apatinib in Treatment of Unresectable Intrahepatic Cholangiocarcinoma: An Observational Study
por: Hu, Yubin, et al.
Publicado: (2020)

Efficacy of Conversion Surgery Following Apatinib Plus Paclitaxel/S1 for Advanced Gastric Cancer With Unresectable Factors: A Multicenter, Single-Arm, Phase II Trial
por: Xu, Zhiyuan, et al.
Publicado: (2021)

Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX)
por: Wang, Yan, et al.
Publicado: (2016)

Activity and safety of apatinib monotherapy or apatinib combined with chemotherapy for patients with metastatic or unresectable osteosarcoma over the age of 40 years: A retrospective analysis
por: Gong, Taojun, et al.
Publicado: (2022)

The Neutrophil-to-Lymphocyte Ratio (NLR) Predicts the Prognosis of Unresectable Intermediate and Advanced Hepatocellular Carcinoma Treated with Apatinib
por: Wang, Huaqi, et al.
Publicado: (2021)

Apatinib Combined With SOX Regimen in Conversion Treatment of Advanced Gastric Cancer: A Case Series and Literature Review
por: Jiang, Dingyi, et al.
Publicado: (2020)

Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination
por: Ju, Shuguang, et al.
Publicado: (2022)

Apatinib combined with SOX regimen for conversion therapy in advanced gastric cancer patients: a retrospective cohort study
por: Deng, Ya-Ya, et al.
Publicado: (2023)

Development and validation of prognostic model based on extragastric lymph nodes metastasis and lymph node ratio in node-positive gastric cancer: a retrospective cohort study based on a multicenter database
por: Zeng, Yi, et al.
Publicado: (2023)

Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Apatinib Compared with Conventional Transarterial Chemoembolization Plus Apatinib in the Treatment of Unresectable Hepatocellular Carcinoma
por: Zhang, Weihua, et al.
Publicado: (2021)

Laparoscopic Versus Open Total Gastrectomy for Advanced Gastric Cancer: A Multicenter, Propensity Score-Matched Cohort Study in China
por: Feng, Xingyu, et al.
Publicado: (2021)

An exploratory clinical trial of apatinib combined with intensity‐modulated radiation therapy for patients with unresectable hepatocellular carcinoma
por: Qiu, Hu, et al.
Publicado: (2022)

Phase 1 trial of apatinib combined with intensity-modulated radiotherapy in unresectable hepatocellular carcinoma
por: Wang, Hongzhi, et al.
Publicado: (2022)

Perioperative Safety and Effectiveness of Neoadjuvant Therapy with Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel Plus Apatinib in Locally Advanced Gastric Cancer
por: Zhang, Yonglei, et al.
Publicado: (2021)

The Efficacy and Safety of Apatinib Treatment for Patients with Unresectable or Relapsed Liver Cancer: a retrospective study
por: Zhen, Liu, et al.
Publicado: (2018)

Protocol for a randomized controlled trial of perioperative S-1 plus oxaliplatin combined with apatinib and camrelizumab in patients with resectable, locally advanced gastric or gastroesophageal junction adenocarcinoma
por: Zheng, Yanan, et al.
Publicado: (2020)

Successful conversion surgery for unresectable gastric cancer with giant para-aortic lymph node metastasis after downsizing chemotherapy with S-1 and oxaliplatin: a case report
por: Serizawa, Akiko, et al.
Publicado: (2018)

POF (paclitaxel/oxaliplatin/5-fluorouracil/leucovorin) vs. SOX/CAPOX/FOLFOX as a postoperative adjuvant chemotherapy for curatively resected stage III gastric cancer: Study protocol for a randomized controlled trial, FNF-014 trial
por: Su, Liyu, et al.
Publicado: (2022)

Neoadjuvant apatinib plus tegafur/gimeracil/oteracil potassium (S‑1)/oxaliplatin chemotherapy vs. chemotherapy alone in patients with locally advanced gastric carcinoma
por: Wang, Zhenfeng, et al.
Publicado: (2022)

Transcatheter arterial chemoembolization combined with apatinib and camrelizumab for unresectable advanced gastric or gastroesophageal junction cancer: a single-arm, single-center, retrospective study
por: Wu, Kunpeng, et al.
Publicado: (2023)

Apatinib inhibits the proliferation of gastric cancer cells via the AKT/GSK signaling pathway in vivo
por: Chen, Yi, et al.
Publicado: (2021)

Therapeutic effect of apatinib on overall survival is mediated by prolonged progression-free survival in advanced gastric cancer patients
por: Huang, Lihong, et al.
Publicado: (2016)

Efficacy of conversion therapy on initially unresectable locally advanced rectal cancer
por: Liu, Tianyu, et al.
Publicado: (2021)

Conversion therapy with tislelizumab for high microsatellite instability, unresectable stage III gastric cancer: a case report
por: Jian, Dan, et al.
Publicado: (2021)

Apatinib enhances chemosensitivity of gastric cancer to paclitaxel and 5-fluorouracil
por: Xu, Zhiyuan, et al.
Publicado: (2019)

Hepatic arterial infusion of oxaliplatin plus raltitrexed in unresectable hepatocellular carcinoma with or without portal vein tumour thrombosis
por: Chen, Shiguang, et al.
Publicado: (2022)

Inflammation-related nomogram for predicting survival of patients with unresectable hepatocellular carcinoma received conversion therapy
por: Wu, Jia-Lin, et al.
Publicado: (2023)

EphA2 affects the sensitivity of oxaliplatin by inducing EMT in oxaliplatin-resistant gastric cancer cells
por: Wen, Qiaocheng, et al.
Publicado: (2017)

Transcatheter arterial chemoembolization plus apatinib with or without camrelizumab for unresectable hepatocellular carcinoma: a multicenter retrospective cohort study
por: Duan, Xuhua, et al.
Publicado: (2023)

A Case Report of Gastrointestinal Hemorrhage and Perforation During Apatinib Treatment of Gastric Cancer
por: Li, Xiao-Fen, et al.
Publicado: (2015)

Efficacy and safety assessment of apatinib in patients with advanced gastric cancer: a meta-analysis
por: Chen, Jianxin, et al.
Publicado: (2018)

Apatinib combined with S-1 as second-line therapy in advanced gastric cancer
por: Qiu, Zhi-Yuan, et al.
Publicado: (2021)

Comparison of two transarterial chemoembolization regimens in patients with unresectable hepatocellular carcinoma: raltitrexed plus oxaliplatin versus 5-fluorouracil plus oxaliplatin
por: Cui, Wei, et al.
Publicado: (2017)

A Phase II Study of Sequential Capecitabine Plus Oxaliplatin Followed by Docetaxel Plus Capecitabine in Patients With Unresectable Gastric Adenocarcinoma: The TCOG 3211 Clinical Trial
por: Chen, Ming-Huang, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_5r4gj9mr5d5nkkmc48tps0a1jm